|
1
|
Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib.
|
Clin Pharmacol Ther
|
2009
|
1.18
|
|
2
|
Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype.
|
Clin Pharmacol Ther
|
2007
|
1.18
|
|
3
|
Phase I study of safety and pharmacokinetics of a human anticytomegalovirus monoclonal antibody in allogeneic bone marrow transplant recipients.
|
Transplantation
|
1991
|
0.99
|
|
4
|
OctreoTher: ongoing early clinical development of a somatostatin-receptor-targeted radionuclide antineoplastic therapy.
|
Digestion
|
2000
|
0.88
|
|
5
|
Population pharmacokinetics/toxicodynamics (PK/TD) relationship of SAM486A in phase I studies in patients with advanced cancers.
|
J Clin Pharmacol
|
2000
|
0.87
|
|
6
|
Mass balance, excretion and metabolism of [¹⁴C] ASA404 in cancer patients in a phase I trial.
|
Cancer Chemother Pharmacol
|
2012
|
0.75
|